Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05022615 · ClinicalTrials.gov registry record
Comparing 3 Imaging Systems
A clinical trial of Diabetic Retinopathy, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 51
- Enrollment target
- 1
- Study location
NCT05022615: Completed study of Diabetic Retinopathy, sponsored by University of Wisconsin, Madison.
NCT05022615 is a study of Diabetic Retinopathy that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 51 participants, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05022615, a study of Diabetic Retinopathy, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the quality of ocular images captured on 3 different cameras of patients with diabetic retinopathy. The study will determine whether diabetic retinopathy assessment is comparable between the cameras. The research is being done to see if a camera takes higher quality pictures over the other cameras. 60 participants will be enrolled into this study. Participants need to have diabetic eye disease. This is a one-time study visit that lasts approximately 1 hour.
Primary Outcome
The images captured within the 7 standard fields on each camera will be graded using the ETDRS severity scale. The total range of possible scores for severity level is from 10 (no DR) to 80 (PDR with vitreous hemorrhage); higher scores indicate increasing severity. Details of ETDRS severity scale: 10-No DR, 15-Probable DR, no MAs, 20-MAs only, 35-Mild NPDR, 43,47-Moderate NPDR, 53-Severe NPDR, 60-PDR status post scatter photocoagulation, 61,65,71-PDR, 80-PDR with vitreous hemorrhage, 90,95-Ungr
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Topcon Camera
- DIAGNOSTIC_TEST Optos Camera
- DIAGNOSTIC_TEST Clarus Camera
Study Locations (1)
Wisconsin
- UW Health - University Station Clinic - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2023-03-07 |
What the finished NCT05022615 record still lists
NCT05022615 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 3 interventions - of which Topcon Camera is the first listed.
NCT05022615 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05022615 about?
NCT05022615 is a clinical study titled "Comparing 3 Imaging Systems". The purpose of this study is to evaluate the quality of ocular images captured on 3 different cameras of patients with diabetic retinopathy. The study will determine whether diabetic retinopathy assessment is comparable between the cameras. The research is being done to see if a camera takes higher ...
What is the current status of trial NCT05022615?
This trial is currently completed. The enrollment target is 51 participants. The study started on 2021-09-29. Estimated completion is 2023-03-07.
What conditions does trial NCT05022615 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT05022615?
The interventions under investigation include: Topcon Camera (DIAGNOSTIC_TEST), Optos Camera (DIAGNOSTIC_TEST), Clarus Camera (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05022615?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05022615 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05022615's enrollment target sits among peer trials
51 42nd of 57 higher than 16 of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
RECRUITING
-
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
RECRUITING · NA
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI